Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for DVAX
18.91
+0.51 (2.77%)
After Hours: 18.77 -0.14 (-0.72%)
Feb 11, 4:11PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.85 - 19.15
52 week 15.86 - 32.49
Open 17.97
Vol / Avg. 1.06M/1.55M
Mkt cap 734.20M
P/E     -
Div/yield     -
EPS -3.45
Shares 38.43M
Beta 2.30
Inst. own 85%
Mar 3, 2016
Q4 2015 Dynavax Technologies Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 14, 2016
Dynavax Technologies Corp at JPMorgan Healthcare Conference
Jan 7, 2016
Dynavax Technologies Corp HEPLISAV-B Phase 3 Data Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -2535.69% -822.35%
Operating margin -2534.68% -827.69%
EBITD margin - -814.97%
Return on average assets -69.36% -52.91%
Return on average equity -84.58% -63.27%
Employees 197 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Company’s pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David L Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 57
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 66
Bio & Compensation  - Reuters
Francis R. Cano Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters